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Summary We evaluated the outcome of treatment for mammary carcinoma in 89 premenopausal women in
relation to the phase of the menstrual cycle. The phase of the cycle was determined on the basis of serum
concentrations of 17p-oestradiol and progesterone. The serum samples were collected 1 day prior to or on the
day of operation. After a median follow-up of 4.1 years no significant differences in disease-free survival were
found between the preovulatory (proliferative), periovulatory and post-ovulatory (luteal) groups. No
differences in survival were found in these subgroups between the No and the N1 subgroup. On the basis of this
study we cannot confirm that the phase of the menstrual cycle during surgery has any effect on the eventual
outcome in mammary carcinoma patients. However larger studies of this type are required before definitive
conclusions can be reached.
Several investigators have reported a relationship between
prognosis and the phase of the menstrual during operation
for patients with mammary carcinoma. In particular, patients
surgically treated in the perimenstrual period (days 0-6 and
21-36) have been reported to have a poorer prognosis
(Hrushesky et al., 1989; Badwe et al., 1991; Gregory et al.,
1992). Other groups have not been able to confirm these
findings (Powles et al., 1991; Rageth et al., 1991; Gnant et
al., 1992). An important drawback of these studies is their
retrospective character with all its possible disadvantages
(Forbes, 1991). One of the shortcomings of retrospective
studies in this respect is the inaccurate estimation of the first
day of the last menstruation since this is not always recorded
exactly in charts (Gruber et al., 1989). We were able to
determine the exact phase of the menstrual cycle in pretreat-
ment sera of a group of women who were treated surgically
for invasive mammary carcinoma.
Patients and methods
Since 1985 pretreatment sera of patients with malignancies
have been collected and stored at -30°C. From this serum
bank 89 sera were available for determining the phase of the
menstrual cycle in premenopausal women who had been
treated surgically for mammary carcinoma. All sera were
drawn on the day of admission (the day before the oper-
ation) or preoperatively on the day of the operation. In all
samples the serum concentrations of 17p-oestradiol (OE2)
and progesterone (P) were determined, using assay proce-
dures described previously (Thomas et al., 1977). By taking
the mid-cycle gonadotrophin (LH and FSH) surge as cycle
day (CD) zero, three different phases of the menstrual cycle
can be distinguished: the preovulatory (proliferative) phase
from CD -12 to CD -3, the periovulatory phase from CD
-3 to CD 1, and the post-ovulatory phase from CD 1 to CD
12. For each of these phases reference values in terms of the
2.5 and 97.5 percentiles of the serum concentrations of OE2
and P are available. These percentiles have been derived from
hormone measurements performed on serum samples col-
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lected daily from 50 women throughout one ovulatory cycle.
Based on these data the patients participating in the present
study could be categorised into the three groups comprising,
respectively, 24, 36 and 29 patients (Table I).
In contrast to other studies, we designated the day of
ovulation as the first day of the menstrual cycle and not the
first day of menstruation.
All patients <T3 underwent either a modified radical
mastectomy or a breast conserving procedure (TI-Tu). In
patients with a T4 tumour a lumpectomy was performed
without axillary clearance. If they were free of disease after
locoregional treatment they were included in the study. As a
rule axillary irradiation was applied in case of extranodal
axillary involvement. All node-positive women (46) received
six courses of adjuvant chemotherapy (cyclophosphamide-
methotrexate-5-fluorouracil). The receptor status of the
tumour was available for 78 patients of this series. The
estimated disease-free survival was calculated according to
the Kaplan-Meier method. The median follow-up period
was 4.1 years.
Results
Table II shows some tumour characteristics of the three
different groups. In each of the three groups the distribution
over the various tumour stages was similar. In addition, no
differences between groups were observed regarding receptor
status. Seven out of 24 (29%) of the preovulatory patients, 7
out of the 36 (19%) patients from the periovulatory group,
and 10 out of the 29 (34%) patients from the post-ovulatory
Table I Oestradiol and progesterone levels ofthe patients, according
to which they were divided into three cycle groups
Follicular phase Periovulatory
day -12-to -3 phase day -3 to Lutealphase day
(n = 24) +I (n = 36) 1-12 (n = 29)
Oestradiol 100-990 86-1700 330-1500
(pmol 1-)
Median 310 460 670
Progesterone <1.30 1.5-9.7 14-81
(nmol 1-l)
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Table n Survey ofthe stage and receptor status ofthe patients in the
three different groups (P>0.05)
Preovulatory Periovulatory Post-ovulatory
phase (follicular) phase phase (luteal)
(n =24) (n = 36) (n = 29)
pT, 14 (58%) 21 (58%) 14 (48%)
PT2 6 (29%) 10 (28%) 12 (41%)
pT3 3 (13%) 1 (3%) 1 (3%)
pT4 0 4 (11%) 2 (7%)
pNo 12 (50%) 16 (48%) 11 (38%)
pN1 12 (50%) 17 (52%) 18 (62%)
ER+ 14 (70%) 21 (66%) 17 (65%)
ER- 6 (30%) 11 (34%) 9 (35%)
PR+ 16 (66%) 25 (78%) 18 (69%)
PR- 8 (33%) 7 (22%) 8 (31%)
group developed metastases. No difference in disease-free
survival was found between the three groups (Figure 1).
Also, in the No and the N, subgroups no difference in
survival was found between the phase groups (P = 0.22 and
P = 0.58 respectively, log-rank test).
Discussion
No relationship between the phase of the menstrual cycle at
the time of primary surgical treatment ofpatients with mam-
mary carcinoma and the outcome could be demonstrated in
our patient group. Furthermore, no differences were found
between the No and the N1 subgroups in any of the three
groups. The latter finding is in contrast to observations by
Senie et al. (1991).
The main difference between our study and those pub-
lished previously by other investigators is the method of
establishing the phase of the menstrual cycle. In all these
studies except one (Ville et al., 1991) the phase of the cycle
was calculated from data mentioned in the patients' charts,
while we determined the phase of the cycle biochemically on
the basis of the hormonal pattern. In this way we were able
to categorise patients exactly as being in the preovulatory
(proliferative, follicular) phase (day - 12 to -3), the perio-
vulatory phase (day-3 to +1) or the post-ovulatory
(secretory, luteal) phase (day +1 to + 12). This method is
more reliable than assessing the phase on the basis of data
recorded in menstrual charts. There is always some inter-
individual difference in the length of the menstrual cycle,
particularly the preovulatory phase. Therefore the exact
phase of the cycle may be calculated wrongly, inducing a
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Figure 1 Disease-free survival of the three menstrual cycle
groups (P>0.05). , preovulatory phase; . periovulatory
phase; ---, post-ovulatory phase.
certain bias (Senie et al., 1991). Our negative finding concern-
ing the relationship between phase and survival is in agree-
ment with two other studies in which the patients were
divided into a proliferative (follicular) and a secretory (luteal)
group (Rageth et al., 1991; Senie et al., 1991). It thus seems
hard to defend the view that the unopposed oestrogen phase
is a dangerous period during which patients with mammary
carcinoma should not be subjected to surgery. If this theory
were true post-menopausal women, who from a hormonal
point of view most resemble women in the proliferative
phase, would display a worse prognosis than premenopausal
women. Moreover, the fact that almost half of premeno-
pausal women would by chance undergo surgery during the
proliferative phase of the menstrual cycle should have a clear
impact on the survival of all premenopausal women com-
pared with post-menopausal women.
We admit that our study group is small and that a larger
group of patients should be investigated in order to give
definitive conclusions. To have an 80% chance ofdetecting a
difference of 50% in recurrence or death rate between the
follicular and luteal phase groups as suggested by Gregory et
al. (1992), at least 200 recurrences or deaths would be
required. Our small study may contribute to the discussion in
a different way from retrospective studies, which also have
limitations.
On the basis of our data there is no support for the finding
of others that the perioperative phase of the menstrual cycle
has an influence on the disease-free survival of patients with
mammary carcinoma. However, larger studies of this type
are required before definitive conclusions can be reached.
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